We welcome Calliope (Calli) Dendrou who joined the Kennedy Institute of Rheumatology this Summer as a Principal Investigator leading a research group. Calli is a leader in cross-disease multiomics and her research focuses on using omics (the study of totality of a molecular process in organisms) to find patterns shared by different inflammatory diseases, so that we can develop better treatments for these life-impacting conditions and repurpose existing treatments to help more people.
The lunch with sandwiches, tea and strawberries was attended by staff and students and provided an opportunity to give some well-earned Long Service Awards.
A new study looked at the effect of patient genetics on their response to secukinumab, an anti-IL17 therapy commonly used to treat inflammatory conditions including arthritis and psoriasis. No link was found between a patient\u2019s genetic variants and their response to therapy. This study challenges the idea that genetics might significantly account for the variable responses to anti-IL17 therapy seen in the clinic.
Huw Colin-York has been awarded a fellowship from the Engineering and Physical Sciences Research Council (EPSRC) to develop synthetic biology tools to understand the immune response.
A new type of macrophages recently identified in atherosclerotic lesions could provide a missing link in understanding the inflammatory origins of the common yet fatal condition.
A team led by Alex Clarke at the Kennedy Institute has identified how high mitochondrial activity regulates antibody responses crucial for immunity but is also necessary for the development of lymphoma.
Insights into a specific macrophage population suggest that these cells could drive inflammation in rheumatoid arthritis. Understanding their complex role could lead to better treatments for patients.
Absci will apply its generative AI platform to The Kennedy Institute\u2019s immunology biorepository to speed the discovery and development of multiple therapies
The Kennedy professor is one of eight researchers from Oxford University who received a prestigious fellowship from the Royal Society in recognition of their work in the fields of science and medicine.
A new study led by Oxford researchers has found vedolizumab can induce remission in patients who have chronic pouchitis after surgery for ulcerative colitis.
A new study in The EMBO Journal has revealed how fat tissues might provide a protective role in intestinal inflammation opening new lines of research into the treatment of inflammatory bowel diseases.
Kennedy Institute researchers Mariana Borsa and Edward Jenkins have both been awarded Sir Henry Wellcome Postdoctoral Fellowships, which give recently qualified postdoctoral researchers the opportunity to start independent research careers.
In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.
We spoke to Irina Udalova and Stephen Sansom about the Kennedy\u2019s new single cell facility and how it will enhance research at the Institute and beyond.
A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.
A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.
Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation\u2019s sixth Emerging Leaders Prize.
![\"A](\"https://www.kennedy.ox.ac.uk/news/bioinformatician-joins-the-kennedy-institute-to-investigate-shared-patterns-of-inflammatory-conditions/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n